On Thursday 30th September 2026, Vitaco Health Group announced that its shareholders, Shanghai Pharmaceuticals and Primavera Capital, have entered into a binding agreement to transfer their entire shareholdings in Vitaco to DCP Capital. On completion, DCP Capital will become Vitaco’s controlling shareholder.  The transaction is subject to customary regulatory approvals and other closing conditions. 

DCP Capital is an international private equity firm with more than 30 years of investment experience and experience in consumer and health and wellness businesses. It has invested in Vitaco because of the strength of our people and brands, our in-house product development and innovation, our integrated manufacturing capability and the growth opportunities in health and wellness markets. 

Vitaco Chief Executive Officer Craig Kearney said: “This agreement marks an important next chapter for Vitaco. DCP Capital has recognised the strength of what we have built and has committed to working with our people to support Vitaco’s next phase of growth.” 

“Vitaco remains a New Zealand and Australian business, with our manufacturing and the home of our brands here. Our strategy, priorities and focus on safety, quality, service and performance remain unchanged.” 

Vitaco’s portfolio includes Healtheries, Musashi, Nutra-Life and Athena. The company will continue supporting its people and delivering for customers, consumers and suppliers throughout the approvals process. 

Mr Kearney thanked Shanghai Pharmaceuticals and Primavera Capital for their support over the past decade, during which Vitaco has invested in its operations, strengthened its portfolio and grown the business.